189 related articles for article (PubMed ID: 12507838)
1. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.
Levin AS; Levy CE; Manrique AE; Medeiros EA; Costa SF
Int J Antimicrob Agents; 2003 Jan; 21(1):58-62. PubMed ID: 12507838
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of multidrug-resistant
Sun L; Wang X; Li Z
Br J Neurosurg; 2018 Dec; 32(6):642-645. PubMed ID: 28431478
[No Abstract] [Full Text] [Related]
3. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii.
Corbella X; Ariza J; Ardanuy C; Vuelta M; Tubau F; Sora M; Pujol M; Gudiol F
J Antimicrob Chemother; 1998 Dec; 42(6):793-802. PubMed ID: 10052904
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam.
Jiménez-Mejías ME; Pachón J; Becerril B; Palomino-Nicás J; Rodríguez-Cobacho A; Revuelta M
Clin Infect Dis; 1997 May; 24(5):932-5. PubMed ID: 9142795
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
Sayin Kutlu S; Saçar S; Süzer T; Cevahir N; Okke D; Dirgen Caylak S; Turgut H
Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
[TBL] [Abstract][Full Text] [Related]
6. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment.
Smolyakov R; Borer A; Riesenberg K; Schlaeffer F; Alkan M; Porath A; Rimar D; Almog Y; Gilad J
J Hosp Infect; 2003 May; 54(1):32-8. PubMed ID: 12767844
[TBL] [Abstract][Full Text] [Related]
7. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.
Urban C; Go E; Mariano N; Berger BJ; Avraham I; Rubin D; Rahal JJ
J Infect Dis; 1993 Feb; 167(2):448-51. PubMed ID: 8421178
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Jellison TK; Mckinnon PS; Rybak MJ
Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849
[TBL] [Abstract][Full Text] [Related]
9. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Lin HS; Lee MH; Cheng CW; Hsu PC; Leu HS; Huang CT; Ye JJ
Infect Dis (Lond); 2015 Jun; 47(6):370-8. PubMed ID: 25746600
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.
Chiu CH; Lee HY; Tseng LY; Chen CL; Chia JH; Su LH; Liu SY
Int J Antimicrob Agents; 2010 Apr; 35(4):382-6. PubMed ID: 20138741
[TBL] [Abstract][Full Text] [Related]
11. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis.
Cawley MJ; Suh C; Lee S; Ackerman BH
Pharmacotherapy; 2002 Apr; 22(4):527-32. PubMed ID: 11939689
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
[TBL] [Abstract][Full Text] [Related]
13. Restricting the use of ampicillin-sulbactam.
Zavascki AP; Sandri AM
J Hosp Infect; 2004 Feb; 56(2):165-6. PubMed ID: 15019231
[No Abstract] [Full Text] [Related]
14. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
16. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
18. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
[TBL] [Abstract][Full Text] [Related]
19. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
Ozseven AG; Sesli Çetin E; Ozseven L
Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
[TBL] [Abstract][Full Text] [Related]
20. Extensively-drug resistant
Gkentzi D; Tsintoni A; Christopoulou I; Mamalis I; Paliogianni F; Assimakopoulos SF; Marangos M; Dimitriou G
J Chemother; 2020 Apr; 32(2):103-106. PubMed ID: 31992156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
